Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis.
Anaphylaxis
KIT p.D816V
drugs
food
hereditary α-tryptasemia
mast cells
tryptase
venom
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
12
11
2022
received:
22
09
2022
accepted:
23
11
2022
medline:
17
4
2023
pubmed:
20
1
2023
entrez:
19
1
2023
Statut:
ppublish
Résumé
The association between Hymenoptera venom-triggered anaphylaxis (HVA) and clonal mast cell-related disorders (cMCD) has been known for decades. However, recent breakthroughs in peripheral blood screening for KIT p.D816V missense variant have revealed the true extent of this clinical association whilst adding to our understanding of the underlying aetiology. Thus, recent large studies highlighted the presence of KIT p.D816V among 18.2% and 23% of patients with severe Hymenoptera venom-triggered anaphylaxis. A significant proportion of those patients have normal serum basal tryptase (BST) levels, with no cutaneous findings such as urticaria pigmentosa or other systemic findings such as organomegaly that would have suggested the presence of cMCD. These findings of an increased prevalence suggest that the impact of cMCD on anaphylaxis could be clinically underestimated and that the leading question for clinicians could be changed from 'how many patients with cMCD have anaphylaxis?' to 'how many patients with anaphylaxis have cMCD?'. The discovery of hereditary α-tryptasemia (HαT)-a genetic trait caused by an increased copy number of the Tryptase Alpha/Beta 1 (TPSAB1) gene-, first described in 2016, is now known to underlie the majority of cases of elevated BST outside of cMCD and chronic kidney disease. HαT is the first common heritable genetic modifier of anaphylaxis described, and it is associated with increased risk for severe HVA (relative risk = 2.0), idiopathic anaphylaxis, and an increased prevalence of anaphylaxis in patients with cMCD, possibly due to the unique activity profile of α/β -tryptase heterotetramers that may potentiate immediate hypersensitivity reaction severity. Our narrative review aims to highlight recent research to have increased our understanding of cMCD and HαT, through recent lessons learned from studying their association with HVA. Additionally, we examined the studies of mast cell-related disorders in food and drug allergy in an effort to determine whether one should also consider cMCD and/or HαT in cases of severe anaphylaxis triggered by food or drugs.
Substances chimiques
Tryptases
EC 3.4.21.59
Arthropod Venoms
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
392-404Informations de copyright
© 2023 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Antonicelli L, Bilò MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol [Internet]. 2022;2(4):341-346.
Bilò MB, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy [Internet]. 2009;39(10):1467-1476.
Bilò BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol [Internet]. 2008;8(4):330-337.
Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG. Diagnosis of Hymenoptera venom allergy. Allergy. 2005;60(11):1339-1349.
Mueller UR. Clinical presentation and pathogenesis. In: Insect Sting Allergy Stuttgart Gustav Fischer (Vol. 1). Gustav Fischer Verlag; 1990.
Golden DBK, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351(7):668-674.
Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr. 1984;104(5):664-668.
Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol. 1984;74(4):494-498.
Pucci S, D'Alò S, De Pasquale T, Illuminati I, Makri E, Incorvaia C. Risk of anaphylaxis in patients with large local reactions to hymenoptera stings: a retrospective and prospective study. Clin Mol Allergy. 2015;13(1):1-3.
Sturm GJ, Kranzelbinder B, Schuster C, et al. Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare. J Allergy Clin Immunol. 2014;133(6):1635-1643.
Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy, Asthma Immunol. 2006;97(1):39-43.
Cianferoni A, Novembre E, Pucci N, Lombardi E, Bernardini R, Vierucci A. Anaphylaxis: a 7-year follow-up survey of 46 children. Ann Allergy Asthma Immunol. 2004;92(4):464-468.
Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy Eur J Allergy Clin Immunol. 2018;73(4):744-764.
Golden DBK, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol. 2009;123(6):1371-1375.
Liew WK, Williamson E, Tang MLK. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123(2):434-442.
Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161(1):15-21.
Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy Eur J Allergy Clin Immunol. 2008;63(2):226-232.
Van Anrooij B, Van Der Veer E, De Monchy JGR, et al. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol. 2013;132(1):125-130.
Golden DBK, Marsh DG, Freidhoff LR, et al. Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol. 1997;100(6):760-766.
Kors J, Doormaal JJ, Monchy JGR. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med [Internet]. 1993;233(3):255-258.
Müller UR, Horat W, Wuthrich B, Conroy M, Reisman RE. Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J Allergy Clin Immunol. 1983;72(6):685-689.
Sperr WR, Valent P. Diagnosis, progression patterns and prognostication in mastocytosis. Expert Rev Hematol. 2012;5(3):261-274.
Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129(11):1420-1427.
Schuler CF, Volertas S, Khokhar D, et al. Prevalence of mastocytosis and Hymenoptera venom allergy in the United States. J Allergy Clin Immunol [Internet]. 2021;148(5):1316-1323.
Zanotti R, Bonifacio M, Isolan C, et al. A multidisciplinary diagnostic approach reveals a higher prevalence of indolent systemic mastocytosis: 15-years' experience of the GISM network. Cancers (Basel) [Internet]. 2021;13(24):6380.
Hershko AY, Shaharabani N, Rosman Y, et al. Hymenoptera venom allergy in a single-center Israeli cohort: clinical and laboratory characteristics. J Allergy Clin Immunol Pract [Internet]. 2019;7(8):2898-2900. doi:10.1016/j.jaip.2019.05.003
Castells MC, Hornick JL, Akin C. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both? J Allergy Clin Immunol Pract. 2015;3(3):350-355.
Bonadonna P, Boni E, Zanotti R. Mastocytosis as a risk factor for insect venom allergy. Allergo J Int [Internet]. 2020;29(3):73-78.
Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere [Internet]. 2021;5(11):e646.
Castells M, Austen KF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol. 2002;127:147-152.
Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol. 2012;157(4):399-405.
Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol [Internet]. 2012;157(3):215-225.
Valent P, Akin C, Gleixner KV, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. Int J Mol Sci. 2019;20(12):2976.
González De Olano D, De La Hoz CB, Núñez López R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy [Internet]. 2007;37(10):1547-1555.
Gülen T, Hägglund H, Dahlén B, Nilsson G. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience. Clin Exp Allergy. 2014;44(1):121-129.
Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123(3):680-686.
Bonadonna P, Zanotti R, Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol. 2010;10(4):347-353.
Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin North Am [Internet]. 2018;38(3):455-468.
Šelb J, Rijavec M, Eržen R, et al. Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone. J Allergy Clin Immunol [Internet]. 2021;148(2):621-626.e7.
Lyons JJ, Chovanec J, O'Connell MP, et al. Heritable risk for severe anaphylaxis associated with increased α-tryptase-encoding germline copy number at TPSAB1. J Allergy Clin Immunol [Internet]. 2021;147(2):622-632.
Dölle-Bierke S, Siebenhaar F, Burmeister T, Worm M. Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the Anaphylaxis Registry (NORA). J Allergy Clin Immunol. 2019;144(5):1448-1450.e1.
Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135-139.
Alvarez-Twose I, González-de-Olano D, Sánchez-Muñoz L, et al. Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. Int Arch Allergy Immunol. 2012;157(3):275-280.
Bonadonna P, Zanotti R, Pagani M, et al. Anaphylactic reactions after discontinuation of hymenoptera venom immunotherapy: a clonal mast cell disorder should be suspected. J Allergy Clin Immunol Pract [Internet]. 2018;6(4):1368-1372.
González-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011;3(5):637-651.
Bonadonna P, Pagani M, Aberer W, et al. Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper. Allergy. 2015;70(7):755-763.
Rama TA, Morgado JM, Henriques A, et al. Mastocytosis presenting with mast cell-mediator release-associated symptoms elicited by cyclo oxygenase inhibitors: prevalence, clinical, and laboratory features. Clin Transl Allergy [Internet]. 2022;12(3):e12132.
Schwaab J, Brockow K, Riffel P, et al. Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosis. Ann Allergy, Asthma Immunol [Internet]. 2022;128(3):314-318.
Jarkvist J, Brockow K, Gülen T. Low frequency of IgE-mediated food hypersensitivity in mastocytosis. J Allergy Clin Immunol Pract [Internet]. 2020;8(9):3093-3101.
Valent P, Spanblochl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992;80(9):2237-2245.
Jara-Acevedo M, Teodosio C, Sanchez-Muñoz L, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol an Off J United States Can Acad Pathol Inc. 2015;28(8):1138-1149.
Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia [Internet]. 2015;29(6):1223-1232.
Kristensen T, Vestergaard H, Møller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagnostics [Internet]. 2011;13(2):180-188.
Greiner G, Gurbisz M, Ratzinger F, et al. Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis. Clin Chem. 2018;64(3):547-555.
De Matteis G, Zanotti R, Colarossi S, et al. The impact of sensitive KIT D816V detection on recognition of indolent systemic mastocytosis. Leuk Res [Internet]. 2015;39(3):273-278.
Weiler CR, Austen KF, Akin C, et al. AAAAI mast cell disorders committee work group report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol [Internet]. 2019;144(4):883-896.
Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract [Internet]. 2019;7(4):1125-1133.e1. doi:10.1016/j.jaip.2019.01.006
Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood [Internet]. 2013;121(16):3085-3094.
Sonneck K, Florian S, Müllauer L, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol [Internet]. 2007;142(2):158-164.
Álvarez-Twose I, González de Olano D, Sánchez-Muñoz L, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol [Internet]. 2010;125(6):1269-1278.e2.
Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol [Internet]. 2019;94(3):363-377.
Pardanani A, Chen D, Abdelrahman RA, et al. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia. 2013;27:2091-2094.
Valent P, Hartmann K, Bonadonna P, et al. Mast cell activation syndromes: collegium internationale allergologicum update. Int Arch Allergy Immunol. 2022;2022:693-705.
Bonadonna P, Gonzalez-de-Olano D, Zanotti R, et al. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract. 2013;1(5):474-478.
Valent P, Akin C, Nedoszytko B, et al. Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine. Int J Mol Sci [Internet]. 2020;21(23):9030.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer Lyon; 2008.
Zanotti R, Bonifacio M, Lucchini G, et al. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. Leukemia [Internet]. 2022;36(2):516-524.
Zanotti R, Bonadonna P, Bonifacio M, et al. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica [Internet]. 2011;96(3):482-484.
Álvarez-Twose I, Zanotti R, González-De-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133(2):520-528.
Pardanani A, Tefferi A. Proposal for a revised classification of systemic mastocytosis. Blood [Internet]. 2010;115(13):2720-2721. doi:10.1182/blood-2009-12-259085
Lyons JJ. Hereditary alpha tryptasemia: genotyping and associated clinical features. Immunol Allergy Clin North Am [Internet]. 2018;38(3):483-495. doi:10.1016/j.iac.2018.04.003
Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet [Internet]. 2016;48(12):1564-1569. doi:10.1038/ng.3696
Chollet MB, Akin C. Hereditary alpha tryptasemia is not associated with specific clinical phenotypes. J Allergy Clin Immunol. 2022;149(2):728-735.e2.
Le QT, Lyons JJ, Naranjo AN, et al. Impact of naturally forming human α/β-tryptase heterotetramers in the pathogenesis of hereditary α-tryptasemia. J Exp Med. 2019;216(10):2348-2361.
Zhang H, Zeng X, He S. Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation. Mediators Inflamm [Internet]. 2014;2014:829068.
Trivedi NN, Tamraz B, Chu C, Kwok PY, Caughey GH. Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol [Internet]. 2009;124(5):1-15.
Le QT, Lotfi-Emran S, Min HK, Schwartz LB. A simple, sensitive and safe method to determine the human α/β-tryptase genotype. PLoS ONE. 2014;9(12):1-13.
Greiner G, Sprinzl B, Górska A, et al. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood [Internet]. 2021;137(2):238-247.
Robey RC, Wilcock A, Bonin H, et al. Hereditary alpha-tryptasemia: UK prevalence and variability in disease expression. J Allergy Clin Immunol Pract [Internet]. 2020;8(10):3549-3556. doi:10.1016/j.jaip.2020.05.057
Giannetti MP, Weller E, Bormans C, Novak P, Hamilton MJ, Castells M. Hereditary alpha-tryptasemia in 101 patients with mast cell activation-related symptomatology including anaphylaxis. Ann Allergy, Asthma Immunol [Internet]. 2021;126(6):655-660. doi:10.1016/j.anai.2021.01.016
Arock M, Hoermann G, Sotlar K, et al. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: status 2022. J Allergy Clin Immunol [Internet]. 2022;149(6):1855-1865.
Gruber BL, Kew RR, Jelaska A, et al. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J Immunol. 1997;158(5):2310-2317.
Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J Clin Invest. 1997;99(6):1313-1321.
Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. . Int Arch Allergy Immunol [Internet]2019;180(1):44-51.
Srisuwatchari W, Tacquard CA, Borushko A, et al. Diagnostic performance of serial serum total tryptase measurement to differentiate positive from negative allergy testing among patients with suspected perioperative hypersensitivity. Clin Exp Allergy [Internet]. 2022;52(2):334-344.
Callesen KT, Poulsen LK, Garvey LH, Jensen BM. Comparing baseline and reaction samples of perioperative anaphylaxis patients reveals IL-6 and CCL2 as potential biomarkers. Clin Exp Allergy. 2021;51(9):1250-1253.
McGrath FM, Francis A, Fatovich DM, et al. Small nucleolar RNA networks are up-regulated during human anaphylaxis. Clin Exp Allergy. 2021;51(10):1310-1321.
Chovanec J, Tunc I, Hughes J, et al. Genetically determining individualized clinical reference ranges for the biomarker tryptase can limit unnecessary procedures and unmask myeloid neoplasms. Blood Adv [Internet]. 2022. doi:10.1182/bloodadvances.2022007936
Bonadonna P, Zanotti R, Pagani M, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy. 2009;64(9):1379-1382.
Luo C, Yuan D, Zhao W, et al. Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress. Mol Med Rep. 2015;12(1):1082-1090.
Konrad FM, Schroeder TH. Anaesthesia in patients with mastocytosis. Acta Anaesthesiol Scand [Internet]. 2009;53(2):270-271.
Russell WJ, Smith WB. Pseudoanaphylaxis. Anaesth Intensive Care [Internet]. 2006;34(6):801-803.
Sheen CH, Schleimer RP, Kulka M. Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation. Allergy [Internet]. 2007;62(5):532-538. doi:10.1111/j.1398-9995.2007.01345.x
Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg [Internet]. 2004;98(2):364-370.
Stellato C, Cirillo R, de Paulis A, et al. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology. 1992;77(5):932-940.
Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol. 2011;21(6):442-453.
Hermans MAW, Arends NJT, Gerth van Wijk R, et al. Management around invasive procedures in mastocytosis: an update. Ann Allergy, Asthma Immunol [Internet]. 2017;119(4):304-309. doi:10.1016/j.anai.2017.07.022
Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology [Internet]. 2014;120(3):753-759.
Dewachter P, Mouton-Faivre C. Concurrent immunoglobulin E-mediated neuromuscular blocking agent allergy in systemic mastocytosis. Ann Allergy Asthma Immunol [Internet]. 2018;120(6):663-664. doi:10.1016/j.anai.2018.02.024
Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a work group report of the mast cells disorder committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol [Internet]. 2019;143(3):880-893.
Weingarten TN, Volcheck GW, Sprung J. Anaphylactoid reaction to intravenous contrast in patient with systemic mastocytosis. Anaesth Intensive Care [Internet]. 2009;37(4):646-649.
Dewachter P, Laroche D, Mouton-Faivre C, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol [Internet]. 2011;77(3):495-501.
Matito A, Alvarez-Twose I, Morgado JM, Sánchez-Muñoz L, Orfao A, Escribano L. Anaphylaxis as a clinical manifestation of clonal mast cell disorders. Curr Allergy Asthma Rep. 2014;14(8):450.
Rama TA, Martins D, Gomes N, et al. Case report: mastocytosis: the long road to diagnosis. Front Immunol. 2021;12(February):1-5.
Sahiner UM, Yavuz ST, Buyuktiryaki B, et al. Serum basal tryptase may be a good marker for predicting the risk of anaphylaxis in children with food allergy. Allergy Eur J Allergy Clin Immunol. 2014;69(2):265-268.
Bizjak M, Maurer M, Košnik M, et al. Severe cold urticaria can point to an underlying clonal mast cell disorder. Allergy Eur J Allergy Clin Immunol. 2021;76(8):2609-2613.
Lyons JJ, Sun G, Stone KD, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 2014;133(5):1471-1474.
Gülen T, Ljung C, Nilsson G, Akin C. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract [Internet]. 2017;5(5):1248-1255.
Cohen SS, Skovbo S, Vestergaard H, et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014;166(4):521-528.
Lyons JJ. Inherited and acquired determinants of serum tryptase levels in humans. Ann Allergy Asthma Immunol [Internet]. 2021;127(4):420-426.
Fernandopulle NA, Zhang SS, Soeding PF, Mackay GA. MRGPRX2 activation in mast cells by neuromuscular blocking agents and other agonists: modulation by sugammadex. Clin Exp Allergy. 2021;51(5):685-695.